#1 Clinical Trials Search in Europe

Corticosteroids For Systemic Use, Plain

This article discusses the use of corticosteroids for systemic use in clinical trials, particularly focusing on their potential role in treating chronic spontaneous urticaria (CSU). Corticosteroids are known for their anti-inflammatory effects and are being studied alongside other medications to improve outcomes for patients with CSU who don’t respond adequately to standard antihistamine treatments.

Table of Contents

What are Corticosteroids?

Corticosteroids for systemic use, also known as systemic corticosteroids, are a group of powerful anti-inflammatory medications used to treat various medical conditions[1]. These drugs are synthetic versions of hormones naturally produced by your adrenal glands, located on top of your kidneys. They are called “systemic” because they affect the entire body when taken orally or through injection.

Medical Conditions Treated

Systemic corticosteroids are used to treat a wide range of medical conditions, particularly those involving inflammation or overactive immune responses. While the clinical trial data provided focuses on Chronic Spontaneous Urticaria (CSU), these medications are commonly used for various other conditions[1]. Some of these include:

  • Chronic Spontaneous Urticaria (CSU): A condition characterized by recurring hives and itching for no apparent reason, lasting for more than six weeks
  • Severe allergic reactions
  • Asthma
  • Rheumatoid arthritis
  • Inflammatory bowel diseases
  • Certain skin conditions
  • Some types of cancer

How Corticosteroids Work

Corticosteroids work by influencing multiple signal transduction pathways in the body[1]. In simpler terms, they:

  1. Reduce inflammation: They decrease the production of inflammatory substances in the body, helping to reduce swelling, redness, and pain.
  2. Suppress the immune system: This can be beneficial in conditions where the immune system is overactive and causing harm to the body.
  3. Affect metabolism: They can influence how the body processes fats, proteins, and carbohydrates.

Administration

According to the clinical trial information, corticosteroids for systemic use are typically administered orally[1]. This means they are taken by mouth, usually in the form of tablets or liquid. The dosage and duration of treatment can vary depending on the specific condition being treated and the individual patient’s needs.

Usage in Clinical Trials

In the clinical trial described, corticosteroids for systemic use are classified as an “auxiliary” medication[1]. This means they are not the primary drug being studied but may be used alongside the main treatment. In this case, they might be used to manage symptoms or side effects related to the primary condition (Chronic Spontaneous Urticaria) or the main drug being tested (remibrutinib).

Potential Side Effects

While the clinical trial data doesn’t provide specific information about side effects, it’s important to note that systemic corticosteroids can have significant side effects, especially when used long-term or in high doses. These may include:

  • Weight gain
  • Increased risk of infections
  • Osteoporosis (bone thinning)
  • High blood pressure
  • Mood changes
  • Skin thinning
  • Cataracts

It’s crucial to discuss potential side effects with your healthcare provider before starting any corticosteroid treatment.

Aspect Details
Study Drug Remibrutinib (LOU064)
Condition Chronic Spontaneous Urticaria (CSU)
Participant Age 12 to less than 18 years
Study Design Double-blind, randomized, placebo-controlled
Duration 24 weeks initial phase, optional 3-year extension
Primary Endpoint Change in UAS7, ISS7, HSS7 at Week 12
Key Inclusion Criteria CSU for ≥6 months, inadequate control with antihistamines
Key Exclusion Criteria Previous use of BTK inhibitors, significant bleeding risk
Corticosteroid Role Mentioned as background therapy (systemic use)

FAQ

  • What is chronic spontaneous urticaria (CSU)? Chronic spontaneous urticaria is a condition characterized by the presence of itchy hives (urticaria) that last for at least six weeks, occurring without any specific trigger.
  • How are corticosteroids being used in the clinical trial for CSU? In this trial, corticosteroids for systemic use are mentioned as a background therapy. The main focus is on testing a new drug called remibrutinib, but corticosteroids may be used as part of the overall treatment approach.
  • Who is eligible for this clinical trial? The trial is for adolescents aged 12 to less than 18 years with CSU that is not adequately controlled by H1-antihistamines for at least 6 months.
  • What are the main goals of this clinical trial? The main objectives are to assess the efficacy, safety, and tolerability of remibrutinib compared to placebo in treating CSU, as well as to evaluate its pharmacokinetics in adolescents.
  • How long does the clinical trial last? The initial double-blind phase lasts 24 weeks, followed by an optional open-label extension for up to 3 years and an additional optional 3-year safety follow-up period.

Ongoing Clinical Trials on Corticosteroids For Systemic Use, Plain

  • Study on the Effectiveness and Safety of Remibrutinib for Teens with Chronic Spontaneous Urticaria Not Controlled by H1-Antihistamines

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy The Netherlands Poland Spain

Glossary

  • Chronic Spontaneous Urticaria (CSU): A skin condition characterized by recurring hives and itching that last for at least six weeks without an identifiable external trigger.
  • Corticosteroids: A class of steroid hormones that reduce inflammation in the body, often used to treat various inflammatory conditions.
  • H1-antihistamines: Medications that block the effects of histamine, a substance in the body that causes allergy symptoms, including hives and itching.
  • Remibrutinib: An investigational drug being studied for its potential to treat chronic spontaneous urticaria in patients who don't respond well to antihistamines.
  • Placebo: An inactive substance that looks like the drug being tested but has no medical effect, used as a control in clinical trials.
  • UAS7: Urticaria Activity Score over 7 days, a measure used to assess the severity of urticaria symptoms.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Open-label extension: A phase of a clinical trial where all participants receive the active treatment and both researchers and participants know what is being administered.
  • Angioedema: Swelling in the deeper layers of the skin, often occurring alongside urticaria.
  • BTK inhibitors: A class of drugs that block an enzyme called Bruton's tyrosine kinase, which plays a role in certain immune responses.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-remibrutinib-for-teens-with-chronic-spontaneous-urticaria-not-controlled-by-h1-antihistamines/